141 related articles for article (PubMed ID: 38070086)
1. Syngeneic Mouse Model of Glioblastoma: Intracranial Implantation of GL261 Cells.
Kaminska P; Cyranowski S; Pilanc P; Malik AR
Methods Mol Biol; 2024; 2746():135-146. PubMed ID: 38070086
[TBL] [Abstract][Full Text] [Related]
2. Implantation of GL261 neurospheres into C57/BL6 mice: a more reliable syngeneic graft model for research on glioma-initiating cells.
Yi L; Zhou C; Wang B; Chen T; Xu M; Xu L; Feng H
Int J Oncol; 2013 Aug; 43(2):477-84. PubMed ID: 23708048
[TBL] [Abstract][Full Text] [Related]
3. Intracranial implantation with subsequent 3D in vivo bioluminescent imaging of murine gliomas.
Abdelwahab MG; Sankar T; Preul MC; Scheck AC
J Vis Exp; 2011 Nov; (57):e3403. PubMed ID: 22158303
[TBL] [Abstract][Full Text] [Related]
4. Tumor Microenvironment and Immune Escape in the Time Course of Glioblastoma.
Virtuoso A; De Luca C; Cirillo G; Riva M; Romano G; Bentivegna A; Lavitrano M; Papa M; Giovannoni R
Mol Neurobiol; 2022 Nov; 59(11):6857-6873. PubMed ID: 36048342
[TBL] [Abstract][Full Text] [Related]
5. SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment.
Moncayo G; Grzmil M; Smirnova T; Zmarz P; Huber RM; Hynx D; Kohler H; Wang Y; Hotz HR; Hynes NE; Keller G; Frank S; Merlo A; Hemmings BA
Neuro Oncol; 2018 Apr; 20(5):621-631. PubMed ID: 29401256
[TBL] [Abstract][Full Text] [Related]
6. Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells.
Clark AJ; Safaee M; Oh T; Ivan ME; Parimi V; Hashizume R; Ozawa T; James CD; Bloch O; Parsa AT
J Transl Med; 2014 Dec; 12():345. PubMed ID: 25464980
[TBL] [Abstract][Full Text] [Related]
7. Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model.
Chae M; Peterson TE; Balgeman A; Chen S; Zhang L; Renner DN; Johnson AJ; Parney IF
Neuro Oncol; 2015 Jul; 17(7):978-91. PubMed ID: 25537019
[TBL] [Abstract][Full Text] [Related]
8. Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes.
Letchuman V; Ampie L; Shah AH; Brown DA; Heiss JD; Chittiboina P
Neurosurg Focus; 2022 Feb; 52(2):E5. PubMed ID: 35104794
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of the effectiveness of poly(ε-caprolactone) lipid-core nanocapsules loaded with methotrexate on glioblastoma multiforme treatment.
Pereira NRC; Loiola RA; Rodrigues SF; de Oliveira CP; Büttenbender SL; Guterres SS; Pohlmann AR; Farsky SH
Int J Nanomedicine; 2018; 13():4563-4573. PubMed ID: 30154652
[TBL] [Abstract][Full Text] [Related]
10. Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.
Renner DN; Jin F; Litterman AJ; Balgeman AJ; Hanson LM; Gamez JD; Chae M; Carlson BL; Sarkaria JN; Parney IF; Ohlfest JR; Pirko I; Pavelko KD; Johnson AJ
PLoS One; 2015; 10(5):e0125565. PubMed ID: 25933216
[TBL] [Abstract][Full Text] [Related]
11. Allergic airway inflammation delays glioblastoma progression and reinvigorates systemic and local immunity in mice.
Poli A; Oudin A; Muller A; Salvato I; Scafidi A; Hunewald O; Domingues O; Nazarov PV; Puard V; Baus V; Azuaje F; Dittmar G; Zimmer J; Michel T; Michelucci A; Niclou SP; Ollert M
Allergy; 2023 Mar; 78(3):682-696. PubMed ID: 36210648
[TBL] [Abstract][Full Text] [Related]
12. Intracranial AAV-IFN-β gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model.
GuhaSarkar D; Neiswender J; Su Q; Gao G; Sena-Esteves M
Mol Oncol; 2017 Feb; 11(2):180-193. PubMed ID: 28098415
[TBL] [Abstract][Full Text] [Related]
13. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
[TBL] [Abstract][Full Text] [Related]
14. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
[TBL] [Abstract][Full Text] [Related]
15. Protein Kinase CK2 Content in GL261 Mouse Glioblastoma.
Ferrer-Font L; Alcaraz E; Plana M; Candiota AP; Itarte E; Arús C
Pathol Oncol Res; 2016 Jul; 22(3):633-7. PubMed ID: 26466942
[TBL] [Abstract][Full Text] [Related]
16. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
17. Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.
Zhang Q; Wang J; Yao X; Wu S; Tian W; Gan C; Wan X; You C; Hu F; Zhang S; Zhang H; Zhao K; Shu K; Lei T
Front Immunol; 2021; 12():637053. PubMed ID: 34108959
[TBL] [Abstract][Full Text] [Related]
18. Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma.
Clark AJ; Fakurnejad S; Ma Q; Hashizume R
J Vis Exp; 2016 Jan; (107):e53287. PubMed ID: 26863490
[TBL] [Abstract][Full Text] [Related]
19. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
[TBL] [Abstract][Full Text] [Related]
20. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.
Candolfi M; Curtin JF; Nichols WS; Muhammad AG; King GD; Pluhar GE; McNiel EA; Ohlfest JR; Freese AB; Moore PF; Lerner J; Lowenstein PR; Castro MG
J Neurooncol; 2007 Nov; 85(2):133-48. PubMed ID: 17874037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
